SHERWIN STEPHEN A 4
Research Summary
AI-generated summary
Biogen (BIIB) Director Stephen A. Sherwin Receives Award
What Happened
Stephen A. Sherwin, a director of Biogen Inc. (BIIB), received a grant of 1,505 restricted stock units (RSUs) on June 9, 2026. The Form 4 reports the acquisition at $0.00 per share (i.e., no cash paid at grant), total reported value $0. This is an award/compensation grant rather than a purchase or sale.
Key Details
- Transaction date: June 9, 2026; Form 4 filed June 11, 2026.
- Transaction type/code: A — Grant/Award/Other acquisition.
- Shares/units granted: 1,505 RSUs; reported acquisition price $0.00 (no cash outlay).
- Shares owned after transaction: not reported in the data provided.
- Footnote: RSUs vest on the earlier of (i) the next annual meeting or (ii) the one-year anniversary of the grant (June 9, 2027).
- No 10b5-1, tax withholding, or cashless-sale details noted in the supplied filing.
Context
RSU grants to directors are commonly part of routine compensation and do not by themselves indicate a buy or sell signal. The $0.00 amount reflects the grant of units rather than a market purchase; value will materialize if and when RSUs vest and convert to shares.